The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma.

The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma.

Show other versions (1)

Dysregulated metabolism is a hallmark of cancer that manifests through alterations in bioenergetic and biosynthetic pathways to enable tumor cell proliferation and survival. Tumor cells exhibit high rates of glycolysis, a phenomenon known as the Warburg effect, and an increase in glutamine consumpti...

Full description

Saved in:
Bibliographic Details
Main Authors: Ethan Emberley, Alison Pan, Jason Chen, Rosalyn Dang, Matt Gross, Tony Huang, Weiqun Li, Andrew MacKinnon, Devansh Singh, Natalija Sotirovska, Susanne M Steggerda, Tracy Wang, Francesco Parlati
Format: article
Language:EN
Published: Public Library of Science (PLoS) 2021
Subjects:
Medicine
R
Science
Q
Online Access:https://doaj.org/article/7d63fa6070aa459a8560bca0f0b6c492
Tags: Add Tag
No Tags, Be the first to tag this record!
Search Result 1
The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma
Get full text
article
Save to List
Saved in:
Show all versions (2)

Similar Items